BridgeBio Pharma Operating Income 2018-2024 | BBIO

BridgeBio Pharma operating income from 2018 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
BridgeBio Pharma Annual Operating Income
(Millions of US $)
2023 $-607
2022 $-512
2021 $-577
2020 $-474
2019 $-266
2018 $-184
2017 $-44
BridgeBio Pharma Quarterly Operating Income
(Millions of US $)
2024-06-30 $-176
2024-03-31 $0
2023-12-31 $-177
2023-09-30 $-158
2023-06-30 $-146
2023-03-31 $-126
2022-12-31 $-129
2022-09-30 $-129
2022-06-30 $-80
2022-03-31 $-174
2021-12-31 $-166
2021-09-30 $-149
2021-06-30 $-94
2021-03-31 $-168
2020-12-31 $-127
2020-09-30 $-120
2020-06-30 $-125
2020-03-31 $-102
2019-12-31 $-79
2019-09-30 $-55
2019-06-30 $-69
2019-03-31 $-64
2018-12-31
2018-09-30 $-41
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.791B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00